Gompertz Law‐Based Biological Age (GOLD BioAge): A Simple and Practical Measurement of Biological Ageing to Capture Morbidity and Mortality Risks

Abstract Biological age reflects actual ageing and overall health, but current ageing clocks are often complex and difficult to interpret, which limits their clinical application. This study introduces a Gompertz law‐based biological age (GOLD BioAge) model designed to simplify the assessment of ageing. We calculated GOLD BioAge using clinical biomarkers and found significant associations between the difference from chronological age (BioAgeDiff) and the risks of morbidity and mortality in the NHANES and UK Biobank. Using proteomics and metabolomics data, we developed GOLD ProtAge and MetAge, which outperformed the clinical biomarker models in predicting mortality and chronic disease risk in UK Biobank. Benchmark analyses demonstrated that the models outperformed common ageing clocks in predicting mortality across diverse age groups in both the NHANES and UK Biobank cohorts. Additionally, a simplified version called Light BioAge is created, which uses three biomarkers to assess ageing. The Light model reliably captured the mortality risk across three validation cohorts (CHARLS, RuLAS, and CLHLS). It significantly predicted the onset of frailty, stratified frail individuals, and collectively identified individuals at high risk of mortality. In summary, the GOLD BioAge algorithm provides a valuable framework for the assessment of ageing in public health and clinical practice.